Table 5

Impact of clinical and biological markers on response to chemotherapya

OverallComplete
ORRχ2PCRRχ2P
Disease extent
 Limited8954
 Extensive781.990.161713.660.000
Sex
 Male8136
 Female952.390.12350.010.93
Performance score
 08642
 1–23810.310.58272.100.15
Treatment arm
 CEE8740
 CEV/PE810.570.45320.560.42
topo IIα
 <30%8538
 30–60%8546
 >60%800.310.86204.000.14
topo IIβ
 <30%8946
 30–60%9148
 >60%715.010.08187.580.02
Ki67
 <30%8421
 30–60%8338
 >30%850.040.98462.520.28
p53
 ≤10%8534
 >10%820.140.71380.140.71
p21
 ≤10%8636
 >10%770.790.38410.210.65
bcl-2
 ≤10%7932
 >10%850.330.56370.170.68
MRP
 ≤10%9032
 >10%830.530.47380.240.62
  • a ORR, overall (complete plus partial) response rate (%); CRR, complete response rate (%); CEE, cyclophosphamide-epirubicine-etoposide; CEV/PE, cyclophosphamide-epirubicine-vincristine alternated with carboplatin-etoposide. All Ps are two-sided and were considered statistically significant at <0.05.